Compass Therapeutics, Inc. 8-K

What Happened
Compass Therapeutics (CMPX) announced results from COMPANION‑002, a randomized Phase 2/3 trial of tovecimig (formerly CTX‑009) plus paclitaxel vs paclitaxel alone in second‑line biliary tract cancer (BTC). The 168‑patient study (randomized 2:1) showed the primary endpoint of overall response rate (ORR) was met: ORR 17.1% with tovecimig + paclitaxel vs 5.3% with paclitaxel alone (p=0.031). Tovecimig also produced a statistically significant improvement in progression‑free survival (median PFS 4.7 vs 2.6 months; HR=0.44, p<0.0001). Overall survival (OS) was not met in the ITT analysis (median OS 8.9 vs 9.4 months; HR=1.05, p=0.78), a result the company attributes to high crossover (54% of control patients crossed over to receive tovecimig). Compass plans to meet with the FDA in advance of a planned BLA submission and presented the data on a webcast April 27, 2026.

Key Details

• Trial: COMPANION‑002, n=168 adults, randomized 2:1 (tovecimig+paci n=111; paclitaxel alone n=57).
• Primary endpoint: ORR 17.1% vs 5.3% (p=0.031), assessed by blinded independent central radiology.
• PFS: median 4.7 months (combo) vs 2.6 months (control), HR=0.44, p<0.0001.
• Crossover/OS: 31 of 57 control patients (54%) crossed over; pooled exposure led to ITT median OS 8.9 months (combo) vs 9.4 months (control); RPSFT adjustment deemed largely uninterpretable.
• Safety: generally consistent with prior data; most common TEAEs in combo arm were hypertension (69%) and fatigue (67%); Grade ≥3 related events included hypertension (44%) and neutropenia (36%).
• Next steps: Compass intends to meet with the FDA prior to a planned BLA and to present the full dataset at a medical conference this year.

Why It Matters
The data show a clear improvement in tumor response and PFS for tovecimig plus paclitaxel in second‑line BTC, which supports the company’s regulatory discussions and planned BLA. However, the OS endpoint was confounded by substantial crossover from the control arm, making survival comparisons inconclusive in this trial. For investors, key takeaways are the positive efficacy signals (ORR, PFS), a tolerable and expected safety profile, an upcoming FDA meeting and BLA intent (regulatory path), and the continued importance of funding and regulatory outcomes for Compass’s near‑term value drivers.